ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

Autor: Marie D. Ralff, Benedito A. Carneiro, Lanlan Zhou, Wen-I Chang, Rohinton Tarapore, Varun V. Prabhu, Joshua N. Honeyman, Attila A. Seyhan, Isacco Ferrarini, Alexander G. Raufi, Lindsey Carlsen, Martin Stogniew, Lee Schalop, Robyn Borsuk, Joshua E. Allen, Aakash Jhaveri, Cassandra Parker, Sara Morrow, Young Lee, Fabio Tavora, Wolfgang Oster, Jocelyn E. Ray, Kelsey E. Huntington, Howard Safran, Anna D Louie, Abed Rahman Kawakibi, Yiqun Zhang, Wafik S. El-Deiry

Publikováno v: Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 12, Pp 725-744 (2020)

ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G protein coupled receptor (GPCR) dopamine receptor D2 (DRD2), and as an allosteric agon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::788cb5d6703ffa407652b681a16c6c03
http://europepmc.org/articles/PMC7588802

Abstract 258: Recombinant human TRAIL or a DR5 agonistic antibody convert the response of non-triple negative breast cancer cells to ONC201 from anti-proliferative to apoptotic

Autor: Marie D. Ralff, Jocelyn E. Ray, Avital Lev, Lanlan Zhou, David T. Dicker, Wafik S. El-Deiry

Publikováno v: Cancer Research. 79:258-258

ONC201 was initially identified as an inducer of cell death through the tumor necrosis factor related apoptosis inducing ligand (TRAIL) pathway. The compound is being tested in patients with a variety of tumor types, including those of the breast. Bo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b5aeb8889092c3f0372be3fb8010266
https://doi.org/10.1158/1538-7445.am2019-258